Importance Tranexamic acid (TXA) is an efficient antifibrinolytic agent; however, concerns
remain about the potential adverse effects, particularly vascular occlusive events, that may …

Background Postpartum haemorrhage (PPH) is the leading cause of maternal mortality
worldwide. Prophylactic uterotonic agents can prevent PPH, and are routinely …

Uncontrolled massive bleeding with subsequent derangement of the coagulation system is a
major challenge in the management of both surgical and seriously injured patients. Under …

Antecedentes La hemorragia posparto (HPP) es una complicación frecuente y
potencialmente mortal del trabajo de parto. Se dispone de varias opciones para prevenir la …

Objective This study aimed to assess the efficacy and safety of prophylactic tranexamic acid
administration vs standard uterotonic agents alone among women undergoing cesarean …

Introduction There are several published clinical trials of the use of tranexamic acid (TXA) in
an obstetric setting, but no consensus on its use or guidelines for management. Material and …

Postpartum haemorrhage (PPH) is a major cause of maternal mortality, accounting for one-
quarter of all maternal deaths worldwide. Uterotonics after birth are the only intervention that …

Background A number of clinical systematic review and meta-analysis have been published
on the use of tranexamic in the obstetric setting. The aim of this meta-analysis was to …

Background: To assess the efficacy and safety of tranexamic acid (TA) in reducing blood
loss and lowering transfusion needs for patients undergoing caesarean section (CS) or …

Background An antifibrinolytic agent that blocks lysine-binding sites on plasminogen
molecules, tranexamic acid reduces bleeding-related mortality in women with postpartum …